JP2015526452A5 - - Google Patents

Download PDF

Info

Publication number
JP2015526452A5
JP2015526452A5 JP2015527878A JP2015527878A JP2015526452A5 JP 2015526452 A5 JP2015526452 A5 JP 2015526452A5 JP 2015527878 A JP2015527878 A JP 2015527878A JP 2015527878 A JP2015527878 A JP 2015527878A JP 2015526452 A5 JP2015526452 A5 JP 2015526452A5
Authority
JP
Japan
Prior art keywords
tetrazol
tetrahydro
cyclohepta
pyridine
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015527878A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015526452A (ja
JP6258937B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/067220 external-priority patent/WO2014029723A1/en
Publication of JP2015526452A publication Critical patent/JP2015526452A/ja
Publication of JP2015526452A5 publication Critical patent/JP2015526452A5/ja
Application granted granted Critical
Publication of JP6258937B2 publication Critical patent/JP6258937B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015527878A 2012-08-24 2013-08-19 新規二環式ピリジン誘導体 Expired - Fee Related JP6258937B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12181739.9 2012-08-24
EP12181739 2012-08-24
PCT/EP2013/067220 WO2014029723A1 (en) 2012-08-24 2013-08-19 New bicyclicpyridine derivatives

Publications (3)

Publication Number Publication Date
JP2015526452A JP2015526452A (ja) 2015-09-10
JP2015526452A5 true JP2015526452A5 (enExample) 2016-10-06
JP6258937B2 JP6258937B2 (ja) 2018-01-10

Family

ID=46851316

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015527878A Expired - Fee Related JP6258937B2 (ja) 2012-08-24 2013-08-19 新規二環式ピリジン誘導体

Country Status (13)

Country Link
US (1) US9562052B2 (enExample)
EP (1) EP2888245B1 (enExample)
JP (1) JP6258937B2 (enExample)
KR (1) KR20150046056A (enExample)
CN (1) CN104583197B (enExample)
AR (1) AR092223A1 (enExample)
BR (1) BR112015002950A2 (enExample)
CA (1) CA2873295A1 (enExample)
ES (1) ES2596243T3 (enExample)
MX (1) MX2015001099A (enExample)
RU (1) RU2648247C2 (enExample)
TW (1) TWI614237B (enExample)
WO (1) WO2014029723A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
LT3418281T (lt) 2012-12-07 2021-01-11 Vertex Pharmaceuticals Inc. Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui
EP2970289A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
EP2970288A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
HUE046727T2 (hu) 2013-12-06 2020-03-30 Vertex Pharma Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai
ES2777608T3 (es) 2014-06-05 2020-08-05 Vertex Pharma Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo
US11179394B2 (en) 2014-06-17 2021-11-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of Chk1 and ATR inhibitors
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
CN107556309B (zh) * 2017-09-11 2020-12-01 浙江永宁药业股份有限公司 多取代四氢萘啶类化合物的药物用途及其制备方法
CN107540672A (zh) * 2017-10-10 2018-01-05 牡丹江医学院 一种治疗肝硬化的药物及其合成方法
AU2021297465A1 (en) 2020-06-27 2023-03-02 Crescenta Biosciences Novel cell metabolism modulating compounds and uses thereof
KR102889668B1 (ko) * 2020-11-03 2025-11-24 주식회사 엘지화학 작물보호제용 신규 화합물
TWI884348B (zh) * 2021-01-06 2025-05-21 日商中外製藥股份有限公司 酸性官能基的烷基化方法
US12054486B2 (en) 2021-09-24 2024-08-06 Xenon Pharmaceuticals Inc. Pyridine derivatives and their use as sodium channel activators
US12138243B2 (en) 2021-12-31 2024-11-12 Crescenta Biosciences Antiviral use of FABP4 modulating compounds
CN114907372B (zh) * 2022-04-26 2023-07-04 黑龙江中医药大学 一种用于治疗多囊卵巢综合征的药物及其制备方法
WO2026036054A1 (en) * 2024-08-09 2026-02-12 Morphic Therapeutic, Inc. Inhibiting alpha-v beta-8 integrin

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW232013B (enExample) * 1992-04-24 1994-10-11 Takeda Pharm Industry Co Ltd
KR100224135B1 (ko) * 1993-01-28 1999-10-15 다께다 구니오 퀴놀린 또는 퀴나졸린 유도체, 그 제조 및 용도
ATE188377T1 (de) * 1993-06-29 2000-01-15 Takeda Chemical Industries Ltd Chinoline oder chinazolin-derivate und deren verwendung zur herstellung eines medikaments für die behandlung von osteoporose
AR008789A1 (es) * 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
TW477787B (en) * 1996-08-27 2002-03-01 Pfizer Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same
DE19741399A1 (de) * 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
JP4473698B2 (ja) * 2003-10-31 2010-06-02 武田薬品工業株式会社 ピリジン化合物
US7521557B2 (en) * 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
JO3077B1 (ar) * 2005-07-28 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينولين مضادة للبكتيريا
US7994321B2 (en) * 2006-08-08 2011-08-09 Hoffmann-La Roche Inc. Substituted thieno[3,2-C]pyridine-7-carboxylic acid derivatives
CN101595109B (zh) * 2006-11-20 2012-09-05 百时美施贵宝公司 作为二肽基肽酶ⅳ抑制剂的7,8-二氢-1,6-二氮杂萘-5(6h)-酮和相关二环化合物及方法
CN101245062A (zh) * 2007-02-16 2008-08-20 中国科学院上海药物研究所 四氢喹啉类化合物、其制备方法及药物组合物
WO2010056631A1 (en) * 2008-11-12 2010-05-20 Schering Corporation Inhibitors of fatty acid binding protein (fabp)
US8889683B2 (en) * 2010-09-27 2014-11-18 Merck Sharp & Dohme Corp. Substituted quinoxalines as inhibitors of fatty acid binding protein
SG11201401937YA (en) * 2011-11-04 2014-05-29 Hoffmann La Roche New aryl-quinoline derivatives

Similar Documents

Publication Publication Date Title
RU2015107979A (ru) Новые бициклические производные пиридина
JP2010524974A5 (enExample)
JP2010524970A5 (enExample)
JP2016500073A5 (enExample)
JP2016519096A5 (enExample)
JP2007504148A5 (enExample)
JP2015500332A5 (enExample)
RU2015100942A (ru) Производное пиперидинилпиразолпиридина
JP2013527173A5 (enExample)
JP2013528591A5 (enExample)
SI3177619T1 (en) 2- (morpholin-4-yl) -1,7-naphthyridines
IL258577A (en) 2,4-dihydroxy-nicotinamides as apj agonists
JP2013525498A5 (enExample)
EP2146716A1 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
JP2012508776A5 (enExample)
JP2017502049A5 (enExample)
JP2016514718A5 (enExample)
JP2017530960A5 (enExample)
JP2019514878A5 (enExample)
RU2016124176A (ru) Композиции тетрагидрохинолинов в качестве ингибиторов бромодомена вет
CA2351725A1 (en) Substituted pyrazoles as p38 kinase inhibitors
IL263511A (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
JP2015508828A5 (enExample)
EP2594270A2 (en) The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc)
JP2016539146A5 (enExample)